| 1 |
Partly verified |
Full text not readStored summary read |
N01 · Efficacy comparison · Preserved-material preparationWhat are the original selected question and subclaim verdict?Required |
The original subclaim concerns weight loss at 12 months, grade C, with the note that 52 weeks produced 2.14 kg more loss than 12 weeks. The parent has C with 50 points and separate axes. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Original wording, subclaim grade/note and parent context for weight loss at 12 months |
Record the original verdict, this preparation and existing-content review as separate events. |
| 2 |
Partly verified |
Full text not readStored summary read |
N02 · Efficacy comparison · Preserved-material preparationDoes the selected comparison concern durations of the same WW program?Required |
The parent outcome is greater weight loss at 12 months than the 12-week program. The comparator also received a 12-week referral to the same WW program and was an active control. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Actual interventions and comparison questions for 52 weeks, 12 weeks and brief intervention |
Present duration comparison and comparisons with other controls as separate questions. |
| 3 |
Partly verified |
Full text not readStored summary read |
N03 · Efficacy comparison · Preserved-material preparationWho was recruited, and what is the applicability?Required |
The trial randomized 1,267 adults with BMI at least 28 in UK primary care. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Primary-care population eligibility, exclusions and baseline characteristics |
Present the recruited population and applicable question scope. |
| 4 |
Partly verified |
Full text not readStored summary read |
N04 · Efficacy comparison · Preserved-material preparationWhat was the research identity of the 52-week intervention?Required |
The original intervention is the commercial WW weight-management program with one group meeting per week for 52 weeks. Its identity as provision of program access is retained. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Program, meetings, referral and actual participation/exposure specifications |
Distinguish the intervention’s research identity from actual participation and exposure. |
| 5 |
Partly verified |
Full text not readStored summary read |
N05 · Efficacy comparison · Preserved-material preparationAre the 12-week active control and brief-intervention group kept separate?Required |
Participants were allocated to brief intervention, 211, WW for 12 weeks, 528, or 52 weeks, 528. The 52- versus 12-week comparison concerns durations of the same program. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Contents, denominators and effect of interest for each comparison group |
Retain all three groups while displaying the selected two-group effect separately. |
| 6 |
Partly verified |
Full text not readStored summary read |
N06 · Efficacy comparison · Preserved-material preparationHave allocation, concealment and masking details been read?Required |
The original evidence describes a three-arm randomized controlled trial. Parent bias B2 is historical verdict information. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Randomization sequence, concealment and outcome-assessor masking materials |
Distinguish the design label from actual implementation details. |
| 7 |
Partly verified |
Full text not readStored summary read |
N07 · Efficacy comparison · Preserved-material preparationAre randomized and measured 12-month denominators distinguished?Required |
The preserved summary records 1,267 allocated (211/528/528), with measured 12-month weight for 823/1,267 (65%). |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Group-specific flow through allocation, follow-up, measurement and analysis |
Present allocation, measurement and analysis denominators separately. |
| 8 |
Partly verified |
Full text not readStored summary read |
N08 · Efficacy comparison · Preserved-material preparationAre missing measurements and multiple imputation retained in interpretation?Required |
The original account of 35% missing measured 12-month weight and use of multiple imputation is retained. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Group-specific missingness reasons, imputation models/assumptions and sensitivity analysis |
Present measured information separately from assumption-based analyses. |
| 9 |
Unverified |
Full text not readStored summary read |
N09 · Efficacy comparison · Preserved-material preparationAre actual attendance, co-exposure and between-group changes verified?Required |
The original materials describe referral allocation and the research identity of one group meeting per week. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Attendance, program use, accompanying management and group-change materials |
Distinguish allocation effects from actual participation and accompanying exposure. |
| 10 |
Partly verified |
Full text not readStored summary read |
N10 · Efficacy comparison · Preserved-material preparationAre weight measurement and timing specified?Required |
The primary endpoint was weight at one year; the evidence records weight at 12 months. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
One-year weight measurement procedure, equipment, units and timing |
Present weight, measurement timing and units together. |
| 11 |
Partly verified |
Full text not readStored summary read |
N11 · Efficacy comparison · Preserved-material preparationAre within-group changes and adjusted between-group differences separate values?Required |
At 12 months, weight change was -4.75 kg with 12 weeks and -6.76 kg with 52 weeks; the adjusted between-group difference was -2.14 kg. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Original within-group changes and adjusted between-group estimate |
Display within-group changes separately alongside the adjusted between-group effect. |
| 12 |
Partly verified |
Full text not readStored summary read |
N12 · Efficacy comparison · Preserved-material preparationWhat are the 12-month between-group effect, interval and test?Required |
The recorded adjusted between-group difference is -2.14 kg, 95% CI -3.05 to -1.22, P<.0001. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Directly reported difference, CI and P value for selected 52 versus 12 weeks |
Present directly reported values with precision and applicability limits. |
| 13 |
Partly verified |
Full text not readStored summary read |
N13 · Efficacy comparison · Preserved-material preparationAre the adjustment model and effect of interest known?Required |
The original account explicitly identifies an adjusted difference and multiple imputation for 35% missingness. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Covariates, analysis population, imputation and model specifications |
Distinguish allocation, participation and completer effects from imputed estimates. |
| 14 |
Partly verified |
Full text not readStored summary read |
N14 · Efficacy comparison · Preserved-material preparationAre the preceding and selected hierarchical comparisons distinguished?Required |
The summary reports that both program groups combined were first compared with brief intervention, passing with -2.71 kg, 95% CI -3.86 to -1.55, P<.0001, before comparing 52 with 12 weeks. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Original testing order, plans and results for preceding and subsequent comparisons |
Link the preceding gatekeeping comparison separately from the selected effect. |
| 15 |
Partly verified |
Full text not readStored summary read |
N15 · Efficacy comparison · Preserved-material preparationWhat is the reading scope for registration and plans?Required |
The account states registration preceded recruitment; the evidence identifier is ISRCTN82857232. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Registration identifier/timing, protocol, SAP and change history |
Distinguish the original identifier from actual material reading and prespecification. |
| 16 |
Partly verified |
Full text not readStored summary read |
N16 · Efficacy comparison · Preserved-material preparationAre sample-size assumptions distinguished from minimum clinical importance?Required |
The summary states that a sample of 1,200 assumed detection of a 1.3 kg difference, which was not a declared minimum clinically important difference. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Sample-size assumptions and declared importance criterion |
Present detection assumptions separately from clinical importance. |
| 17 |
Partly verified |
Full text not readStored summary read |
N17 · Efficacy comparison · Preserved-material preparationAre 12-month and 24-month effects distinguished?Required |
The recorded 24-month difference is -1.32 kg, 95% CI -2.46 to -0.18, P=.0231. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Actual comparison, effect, denominator and subsequent exposure by time point |
Display one-year and 24-month estimates separately. |
| 18 |
Partly verified |
Full text not readStored summary read |
N18 · Efficacy comparison · Preserved-material preparationDoes 12-month superiority establish five-year maintenance?Required |
The original account records a null 52- versus 12-week result at five years: -0.80 kg, 95% CI -2.13 to 0.54. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Direct five-year comparison and uncertainty in the same trial |
Distinguish short-term superiority from the long-term null result. |
| 19 |
Partly verified |
Full text not readStored summary read |
N19 · Efficacy comparison · Preserved-material preparationAre five-year measurements and follow-up denominators separate from 12 months?Required |
The long-term citation is the WRAP five-year follow-up. Measured 12-month weight in 823 and 35% missingness concern one year. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Five-year follow-up, measurements, group denominators, missingness and analysis assumptions |
Separate actual observed and analysis denominators by time point. |
| 20 |
Partly verified |
Full text not readStored summary read |
N20 · Efficacy comparison · Preserved-material preparationIs weight loss being extended to other clinical outcomes?Required |
The currently preserved evidence has weight at 12 months as its primary endpoint. The long-term citation title mentions effectiveness and cost-effectiveness. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Direct outcomes for weight versus clinical events, function and quality of life |
Distinguish weight change from direct evidence for other outcomes. |
| 21 |
Partly verified |
Full text not readStored summary read |
N21 · Efficacy comparison · Preserved-material preparationAre the main report, five-year follow-up and sibling sheets kept within the same trial?Required |
The 2017 WRAP main report and 2022 five-year follow-up are identified as reports of the same trial. The two sheets share parent summary 2964 and two subclaim records. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
WRAP bibliography, registration, participants and follow-up relationships |
Distinguish report slots from trial and participant units. |
| 22 |
Partly verified |
Full text not readStored summary read |
N22 · Efficacy comparison · Preserved-material preparationAre other independent replications and generalization materials available?Required |
The preserved summary identifies only the WRAP main report and same-trial long-term follow-up. Parent replication R1 is a historical label. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Actual independent reports for the same comparison, population and duration |
Distinguish follow-up in the same cohort from other independent replication. |
| 23 |
Partly verified |
Full text not readStored summary read |
N23 · Efficacy comparison · Preserved-material preparationAre consortium funding, industry funding and program access distinguished?Required |
Public/nonprofit consortium funding accompanied WW International industry-partner funding and program access. The UK MRC Industrial Collaboration Award relationship is retained. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Research funding, program support, contracts and sponsor-role disclosures |
Display public, nonprofit and industry funding separately from program support. |
| 24 |
Partly verified |
Full text not readStored summary read |
N24 · Efficacy comparison · Preserved-material preparationAre WW funding to authors’ institutions and employee authors distinguished?Required |
The account states that five authors disclosed WW research funding received by their institutions. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Author-specific affiliations, contributions, institutional support and COI disclosures |
Distinguish institutional support from employment, analysis and publication roles. |
| 25 |
Unverified |
Full text not readStored summary read |
N25 · Efficacy comparison · Preserved-material preparationAre contracted analysis, medical writing, publication fees and program control known?Required |
The summary describes industry funding, program access and funding relationships involving authors’ institutions. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Industry-partner/researcher, analysis, writing and publication role disclosures |
Present reported support separately from unverified roles. |
| 26 |
Partly verified |
Full text not readStored summary read |
N26 · Supplementary harm evidenceWhat is the scope of the intervention-related adverse-event account?Supplementary |
The summary states that the paper reported no intervention-related adverse events but did not provide a group-specific table of all adverse events. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Event definitions, causal classification, collection and group-specific exposure denominators |
Distinguish all events from intervention-related events. |
| 27 |
Partly verified |
Full text not readStored summary read |
N27 · Supplementary harm evidenceIs equal safety between the two referral durations established?Supplementary |
The preserved safety account states that without an all-event table by group, equal safety between the durations cannot be concluded. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Duration-specific harms comparisons, estimates, intervals and denominators |
Distinguish efficacy superiority from harms comparisons and equivalence. |
| 28 |
Unverified |
Full text not readStored summary read |
N28 · Supplementary harm evidenceAre separate long-term and rare-harm materials required?Supplementary |
The main-report account describes no intervention-related adverse events and absence of an all-event table; the subsequent bibliography concerns five-year follow-up. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Actual long-term follow-up, discontinuation, exposure and rare-event materials |
Present long-term weight effects separately from long-term safety information. |
| 29 |
Partly verified |
Full text not readStored summary read |
N29 · Efficacy comparison · Preserved-material preparationAre the read summary and unread external materials distinguished?Required |
What was actually read was the complete preserved parent JSON summary. The main-report PubMed and five-year repository URLs are linked as in the originals. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Preserved JSON, bibliography links, abstract, full-text, registration and planning status |
Show summary reading separately from material-specific external nonreading |
| 30 |
Partly verified |
Full text not readStored summary read |
N30 · Efficacy comparison · Preserved-material preparationAre original verdict/history and candidate states separate from preparation?Required |
Korean/English, original axes, 2026-08-26 reference date, empty corrections/deliberation and subclaims are retained in the complete summary. Original candidate pending/eligible states are preserved history. |
Preparation displays information, scope and unverified matters in the read preserved materials; this is not completed content review or a new clinical efficacy/harms verdict. |
Korean/English, axes, dates, corrections, selected record link and preparation events |
Record original history, preparation and existing-content review as separate events. |